negatives Remoxy Panel Vote (3-14)
Kapitalerhöhung zu 1,15$
"Pain Therapeutics, Inc. a biopharmaceutical company, today announced the closing of its previously announced registered direct offering of 8,860,778 shares of its common stock, which was priced at-the-market at a purchase price of $1.15 per share, for gross proceeds of approximately $10.19 million."
Wenn zu 6,8 Mio Aktien noch 8,9 Mio. neue Aktien hinzukommen kann man schon von einer enormen Verwässerung reden.
Investor Call am 4. Oktober 2018
"Pain Therapeutics, Inc. , a biopharmaceutical company, today announced that it will host a live conference call to provide a strategic update regarding its business, its science and its pipeline. The call is scheduled to be held Thursday, October 4th at 10 AM Eastern time, 9 AM Central time."
Pain Therapeutics bekommt 3,5 Mio. $ "Forschungsgelder" vom NIH
Die Marktteilnehmer hatten offenbar andere News erwartet/erhofft.
Operating Highlights for 2018 and Forecast for 2019--